Joung-Liang Lan

Joung-Liang Lan


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 December 2018 in Arthritis Research & Therapy
Verified
Journal Article
Open access
PDF file
Yi-Ming ChenYi-Ming Chen
Yi-Ming Chen
CCChun-Yu Chang
Chun-Yu Chang
HCHsin-Hua Chen
Hsin-Hua Chen
CHChia-Wei Hsieh
Chia-Wei Hsieh
KTKuo-Tung Tang
Kuo-Tung Tang
Der-Yuan ChenDer-Yuan Chen
Der-Yuan Chen
Increasing evidence indicates a pathogenic role of deregulated autophagy in rheumatoid arthritis (RA). We examined the relationship between autophagy and inflammatory parameters in patients with RA receiving biologic therapy. In 72 patients with RA and 20 healthy control subjects (HC), autophagosome levels were determined by the mean fluorescence intensity (MFI) of autophagosomotropic dye incorporated into circulating immune cells, and p62 expression levels in immune cells were measured by flow cytometry. We used immunoblotting to examine protein expression of LC3-II and p62 in peripheral blood mononuclear cells. Patients with RA had significantly higher levels of autophagosome reflected by MFI of Cyto-ID in circulating lymphocytes, monocytes, and granulocytes (median values, 3.6, 11.6, and 64.8, respectively) compared with HC (1.9, 6.0, and 35.8; respectively) (all p < 0.001). p62 MFI levels in lymphocytes and granulocytes from patients with RA (17.1 and 8.6, respectively) were significantly lower than those in the corresponding cells from HC (20.2, p < 0.05; and 13.1, p < 0.001, respectively). Significantly higher levels of LC3-II protein expression in contrast to lower p62 protein levels were observed in patients with RA than in HC. The autophagosome levels in immune cells were significantly correlated with inflammatory parameters in patients with RA, and they were significantly decreased with disease remission after treatment with tumor necrosis factor-α inhibitors or interleukin-6 receptor inhibitor. Elevated autophagy with significant correlation to inflammation suggests the involvement of autophagy in RA pathogenesis. The effectiveness of biologic therapy might be partly related to the downregulation of autophagy expression.

22 May 2019 in International Journal of Rheumatic Diseases
Verified
Journal Article
Closed access
PDF file
Yi-Ming ChenYi-Ming Chen
Yi-Ming Chen
HCHsin‐Hua Chen
Hsin‐Hua Chen
WHWen‐Nan Huang
Wen‐Nan Huang
YCYi‐Hsing Chen
Yi‐Hsing Chen
THTsu‐Yi Hsieh
Tsu‐Yi Hsieh
Der-Yuan ChenDer-Yuan Chen
Der-Yuan Chen

3 February 2019 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
CCChun-Yu Chang
Chun-Yu Chang
CCChu-Huang Chen
Chu-Huang Chen
Yi-Ming ChenYi-Ming Chen
Yi-Ming Chen
THTsu-Yi Hsieh
Tsu-Yi Hsieh
Ming-Yi ShenMing-Yi Shen
Ming-Yi Shen
Der-Yuan ChenDer-Yuan Chen
Der-Yuan Chen
L5, the most negatively charged subfraction of low-density lipoprotein (LDL), is implicated in atherogenesis. We examined the relationship between plasma L5 levels and the occurrence of subclinical atherosclerosis in patients with rheumatoid arthritis (RA). Using anion-exchange purification with fast-protein liquid chromatography, we determined the proportion of plasma L5 of LDL (L5%) in 64 RA patients and 12 healthy controls (HC). Plasma L5% and L5 levels were significantly higher in RA patients (median, 1.4% and 1.92 mg/dL) compared with HC (0.9%, p < 0.005; and 1.27 mg/dL, p < 0.05) and further increased in patients with subclinical atherosclerosis (2.0% and 2.88 mg/dL). L5% and L5 levels decreased in patients after 6-months of therapy (p < 0.01). Subclinical atherosclerosis was indicated by plaque and intima-media thickness determined by carotid ultrasonography. Using multivariate analysis, L5% and L5 levels are revealed as the predictors of subclinical atherosclerosis (odds ratio, 4.94 and 1.01; both p < 0.05). Receiver operating characteristic curves showed that cut-off values of L5% ≥ 1.45% and L5 levels ≥ 2.58 mg/dL could predict subclinical atherosclerosis in patients (both p < 0.001). Immunoblotting showed that the expression levels of lectin-like oxidized LDL receptor-1 (LOX-1) was increased in RA patients. Together, our findings suggest that plasma L5% and L5 levels may be predictors of cardiovascular risk in RA patients.

24 May 2019 in Osteoporosis International
Verified
Journal Article
Closed access
PDF file
WHW.-J. Hong
W.-J. Hong
WCW. Chen
W. Chen
KYK.-J. Yeo
K.-J. Yeo
PHP.-H. Huang
P.-H. Huang
Der-Yuan ChenDer-Yuan Chen
Der-Yuan Chen
JLJoung-Liang Lan
Joung-Liang Lan

15 April 2022 in Biomedicines
Verified
Journal Article
Open access
PDF file
NTNi Tien
Ni Tien
YCYu-Chang Chang
Yu-Chang Chang
PCPo-Ku Chen
Po-Ku Chen
HLHui-Ju Lin
Hui-Ju Lin
SCShih Hsin Chang
Shih Hsin Chang
Der-Yuan ChenDer-Yuan Chen
Der-Yuan Chen
Patients with immune-mediated inflammatory diseases (IMID) were seldom enrolled in the studies of SARS-CoV-2 vaccines, and real-world data regarding the immunogenicity of different types of vaccines is limited. We aimed to assess the immunogenicity and safety of three types of vaccines (AZD1222, mRNA-1273, and BNT162b2) in 253 patients with IMID and 30 healthcare workers (HCWs). Plasma levels of IgG-antibody against SARS-CoV-2 targeting the receptor-binding domain of spike protein (anti-S/RBD-IgG) were determined by chemiluminescent immunoassay 3–4 weeks after the first-dose and second-dose vaccination. The positive rate and titers of anti-S/RBD-IgG were significantly higher in mRNA-1273 or BNT162b2 than in the AZD1222 vaccine. Immunogenicity was augmented after the second dose of any vaccine type in all IMID patients, suggesting that these patients should complete the vaccination series. Anti-S/RBD-IgG titers after first-dose vaccination were significantly lower in RA patients than pSS patients, but there was no significant difference after second-dose vaccination among five groups of IMID patients. The positive rate and titers of anti-S/RBD-IgG were significantly lower in patients receiving abatacept/rituximab therapy than in those receiving other DMARDs. All three SARS-CoV-2 vaccines showed acceptable safety profiles, and the common AEs were injection site reactions. We identified SLE as a significant predictor of increased autoimmunity and would like to promote awareness of the possibility of autoimmunity following vaccination.

18 November 2016 in PLOS ONE
Verified
Journal Article
Open access
PDF file
DCDer-Yuan Chen
Der-Yuan Chen
JLJu-Pi Li
Ju-Pi Li
Yi-Ming ChenYi-Ming Chen
Yi-Ming Chen
TLTsai-Ling Liao
Tsai-Ling Liao
HCHsin-Hua Chen
Hsin-Hua Chen
JLJoung-Liang Lan
Joung-Liang Lan
QuantiFERON-TB-Gold (QFT-G) conversion is frequently observed in rheumatoid arthritis (RA) patients receiving biologic therapy. However, there have not been any known biomarkers available for detecting tuberculosis (TB) in QFT-G converters. We aimed to evaluate clinical utility of cytokines/chemokines for detecting TB in patients with QFT-G conversion. Among a total of 227 RA patients who underwent QFT-G assay, 187 QFT-G-negative patients received biologic therapy without isoniazid prophylaxis. QFT-G assay was repeated at week 52 of biologic therapy or at the time of TB diagnosis. Levels of cytokines/chemokines were determined by magnetic bead array or ELISA in QFT-G converters and 12 non-RA patients with TB (non-RA TB). QFT-G conversion was found in 54 (28.9%) of 187 baseline QFT-G-negative patients, of which 7 (13.0%) developed active TB during the one-year follow-up period. Among the examined cytokines/chemokines, non-stimulated and TB-antigen-stimulated neopterin levels were significantly higher in RA patients who developed TB (RA-TB) (median, 24.5pg/ml and 23053pg/ml, respectively) and non-RA TB patients (12.2pg/ml and 9633pg/ml, respectively) compared with QFT-G converters without TB (3.0pg/ml and 2720pg/ml, respectively, both p<0.001). Rising levels of neopterin relative to baseline (non-stimulated levels, 4.4pg/ml vs. 24.5pg/ml; TB-antigen-stimulated levels, 1801pg/ml vs. 23053pg/ml) were observed in QFT-G converters who developed TB. A high proportion (85.7%) of QFT-G converters with high plasma neopterin levels developed TB during the one-year follow-up period. In conclusion, RA patients with QFT-G conversion during the period of biologic therapy should be carefully monitored for elevation of neopterin levels, which is associated with TB risk in QFT-G converters, particularly in TB-endemic areas.